| Catalog No | Package | Original Price | Price | Inventory | Quantity | Operating |
|---|---|---|---|---|---|---|
| SBP01695-5mg | 5mg | $165.00 | Sign in |
|
Storage conditions：Short-term storage at 2~8℃, long-term storage at -20 ~ -80℃
Dehydro-α Alpha-lapachone (CAS No.: 15297-92-4) is a naphthoquinone compound derived from natural plants. Due to its unique chemical structure and diverse bioactivity, it has attracted widespread attention in the field of natural product pharmacology in recent years. α As a dehydroderivative, dehydro-alpha-lapachone exhibits significant pharmacological activity in anti-tumor, anti-inflammatory, and antimicrobial aspects, especially showing great potential in tumor treatment. Its mechanism of action involves multiple cell signaling pathways and key molecular targets, covering multiple aspects such as apoptosis regulation, cell cycle arrest, and tumor microenvironment regulation.
This paper will systematically review the chemical structure and physicochemical properties of dehydro-alpha-lapaquinone, plant origin and extraction methods, pharmacological activity and mechanism, druggability evaluation and pharmacokinetic characteristics, and finally discuss its clinical application prospects and future development directions, aiming to provide theoretical basis and reference for in-depth research and drug development of this natural product.
Dehydro-Alpha-Lapaquinone belongs to the naphthoquinone class of compounds, with a molecular formula of C15H12O3 and a molecular weight of 240.2580. Its structural core is the naphthoquinone skeleton, and dehydrogenation allows it to form specific double bonds in the molecule, giving it a unique electron distribution and spatial configuration. The compound has a LogP value of 2.9125, indicating moderate lipid solubility, which facilitates cell membrane penetration and distribution in vivo. The polar surface area (TPSA) is 43.37 Ų, indicating moderate polarity and favorable binding to biomacromolecules.
Low water solubility (0.0122 mg/mL) suggests limited solubility in the aqueous phase, which may affect its bioavailability. The high permeability of the blood-brain barrier indicates its potential to act on central nervous system-related diseases. The hERG channel inhibition test was negative, indicating a low risk of cardiotoxicity. The Ames test scored 1.5, indicating low genotoxicity risk and good safety.
In summary, dehydro-alpha-lapaquinone possesses excellent physicochemical properties and is suitable for further drug development and structural optimization.
Dehydro-Alpha-Lapaquinone mainly comes from the Brazilian species of the Bignoniaceae family—Tabebuia spp., especially species such as Tabebuia avellanedae and Tabebuia impetiginosa. The bark and wood of the Lapa tree are rich in various naphthoquinone compounds, with dehydro-alpha-Lapaquinone being one of the important active components.
Traditional extraction methods usually use organic solvent extraction such as ethanol, methanol, or ethyl acetate, with multiple extractions of the dried and crushed bark, followed by separation and purification through liquid-liquid partitioning and column chromatography. Modern extraction technologies such as ultrasound-assisted extraction, microwave-assisted extraction, and supercritical CO2 extraction have been applied to improve extraction efficiency and purity.
During purification, methods such as silica gel column chromatography and reversed-phase high-performance liquid chromatography (RP-HPLC) are widely used to obtain high-purity dehydro-alpha-lapaquinone. Structural identification mainly relies on technologies such as nuclear magnetic resonance (NMR), mass spectrometry (MS), infrared spectroscopy (IR), and ultraviolet spectroscopy (UV) to ensure the accuracy of the compound's structure.
Dehydro-alpha-lapaquinone exhibited significant cytotoxicity and antiproliferative effects in various tumor cell lines. Its anti-tumor activity covers various solid tumors including lung cancer, breast cancer, liver cancer, and colorectal cancer. In vitro experiments have shown that this compound can induce tumor cell apoptosis, inhibit the cell cycle process, and inhibit the ability of tumor cells to migrate and invade.
Animal model studies further confirmed the antitumor effects of dehydro-alpha-laquinone, manifesting as significant tumor size reduction and increased tumor cell apoptosis rates. Additionally, this compound has low toxicity to normal cells and demonstrates good selectivity.
In addition to its antitumor effects, dehydro-alpha-lafaquinone also exhibits certain anti-inflammatory, antioxidant, and antimicrobial activities. Relevant studies have shown that it can regulate the expression of inflammatory factors, reduce oxidative stress damage, and inhibit certain bacteria and fungi. These activities provide a theoretical basis for its potential applications in inflammatory and infectious diseases.
The antitumor mechanisms of dehydro-alpha-lapaquinone are complex and diverse, involving multiple signaling pathways and key molecular targets.
STAT3: This transcription factor is abnormally activated in various tumors, promoting cell proliferation and immune escape. Dehydro-alpha-lapaquinone inhibits STAT3 phosphorylation and nuclear translocation, blocking the expression of its downstream target genes and suppressing tumor progression.
MAPK1: As a key member of the MAPK signaling pathway, MAPK1 is involved in cell proliferation and differentiation. Dehydro-alpha-lapaquinone regulates MAPK1 activity and intervenes in tumor cell growth signaling.
In summary, dehydro-alpha-lapaquinone demonstrates broad-spectrum anti-tumor activity through multi-target and multi-pathway synergistic effects, providing a solid molecular foundation for its development as an anticancer drug.
The molecular weight of dehydro-alpha-laquinone (240.26 Da) meets the Lipinski rule requirement for molecular weight less than 500 Da. Its LogP value is 2.91, which is within the ideal lipophilic range, which facilitates cell membrane permeability. TPSA is 43.37 Ų, and its low polarity aids oral absorption and intracellular distribution.
Low water solubility (0.0122 mg/mL) may limit its bioavailability, but it can be improved through formulation techniques such as nanoparticles and liposomes. The high permeability of the blood-brain barrier suggests its potential application in central nervous system diseases. The hERG channel showed no significant inhibitory effect, reducing the risk of cardiotoxicity. Ames test results showed low genotoxicity risk and good safety.
Currently, pharmacokinetic research on dehydro-alpha-lafaquinone is relatively limited. Preliminary in vivo studies have shown that this compound is rapidly absorbed orally, has a moderate plasma half-life, is widely distributed, and can effectively enter tissues, especially tumor tissues. Its metabolic pathway mainly involves redox reactions in the liver and glucuronic acid binding, with excretion primarily through bile and urine.
In the future, further systematic pharmacokinetic and toxicological studies are needed to clarify in vivo kinetic characteristics, metabolites, and safe dosage ranges, providing a basis for clinical application.
Dehydro-Alpha-Lapaquinone, with its multi-target antitumor mechanism and favorable druggability parameters, demonstrates broad clinical application prospects. Especially in the field of oncology treatment, this compound is expected to serve as a candidate for monotherapy or combination therapy, overcoming the resistance and side effect issues of traditional chemotherapy drugs.
Moreover, its blood-brain barrier permeability makes it possible for treating brain tumors and neurological diseases. In the future, combining nanotechnology with targeted delivery systems is expected to further enhance efficacy and safety.
However, clinical research on dehydro-alpha-laquinone is still in its early stages, urgently requiring systematic preclinical safety evaluations and clinical trials to verify its efficacy and safety. At the same time, in-depth analysis of its mechanism of action and pharmacokinetic characteristics will provide a solid foundation for its clinical translation.
Future research should also focus on structural optimization, dosage form innovation, and synergy with other antitumor drugs to promote the clinical application of dehydro-alpha-lafaquinone.
Dehydro-alpha-lapaquinone, as a naphthoquinone compound derived from natural plants, has become a hot topic in pharmacological research of natural products due to its unique chemical structure and multi-target antitumor activity. It exhibits good pharmacological activity in multiple aspects such as antitumor and anti-inflammatory properties, with mechanisms of action covering multiple aspects including apoptosis regulation, signal transduction inhibition, and tumor microenvironment regulation.
Druggability evaluation indicates that it has promising drug development potential, especially the permeability of the blood-brain barrier and low risk of cardiac toxicity, which provide advantages for its clinical application. Although clinical research is still in its early stages, dehydro-alpha-laquinone has broad prospects as a new anti-tumor drug.
In the future, it is necessary to strengthen pharmacokinetics, toxicology, and preclinical research, integrate modern drug delivery technologies, promote its clinical application, and achieve innovative breakthroughs in natural products in anti-tumor treatment.
